Stephen Salloway

59.6k total citations · 12 hit papers
180 papers, 13.9k citations indexed

About

Stephen Salloway is a scholar working on Psychiatry and Mental health, Physiology and Pharmacology. According to data from OpenAlex, Stephen Salloway has authored 180 papers receiving a total of 13.9k indexed citations (citations by other indexed papers that have themselves been cited), including 99 papers in Psychiatry and Mental health, 87 papers in Physiology and 32 papers in Pharmacology. Recurrent topics in Stephen Salloway's work include Dementia and Cognitive Impairment Research (93 papers), Alzheimer's disease research and treatments (85 papers) and Cholinesterase and Neurodegenerative Diseases (30 papers). Stephen Salloway is often cited by papers focused on Dementia and Cognitive Impairment Research (93 papers), Alzheimer's disease research and treatments (85 papers) and Cholinesterase and Neurodegenerative Diseases (30 papers). Stephen Salloway collaborates with scholars based in United States, United Kingdom and Sweden. Stephen Salloway's co-authors include Kaj Blennow, Bart De Strooper, Giovanni B. Frisoni, Philip Scheltens, Monique M.B. Breteler, Wiesje M. van der Flier, Paul Malloy, Jeffrey L. Cummings, Reisa A. Sperling and Paul Aisen and has published in prestigious journals such as New England Journal of Medicine, The Lancet and NeuroImage.

In The Last Decade

Stephen Salloway

175 papers receiving 13.5k citations

Hit Papers

Alzheimer's disease 2006 2026 2012 2019 2016 2021 2008 2021 2008 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Alzheimer's disease
    2016 2.4k citations Kaj Blennow, Stephen Salloway et al. profile →
  2. Donanemab in Early Alzheimer’s Disease
    2021 969 citations Mark A. Mintun, Albert Lo et al. New England Journal of Medicine profile →
  3. Deep Brain Stimulation of the Ventral Capsule/Ventral Striatum for Treatment-Resistant Depression
    2008 631 citations Paul Malloy, Stephen Salloway et al. profile →
  4. Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group
    2021 598 citations Bruno Dubois, Nicolas Villain et al. The Lancet Neurology profile →
  5. Deep brain stimulation of the ventral internal capsule/ventral striatum for obsessive-compulsive disorder: worldwide experience
    2008 532 citations Paul Malloy, Stephen Salloway et al. profile →
  6. Three-Year Outcomes in Deep Brain Stimulation for Highly Resistant Obsessive–Compulsive Disorder
    2006 519 citations Paul Malloy, Stephen Salloway et al. profile →
  7. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease
    2021 411 citations Stephen Salloway, Frederik Barkhof et al. JAMA Neurology profile →
  8. The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease
    2022 307 citations Oskar Hansson, Adam L. Boxer et al. Alzheimer s & Dementia profile →
  9. Aducanumab: Appropriate Use Recommendations
    2021 207 citations Paul Aisen, Liana G. Apostolova et al. The Journal of Prevention of Alzheimer s Disease profile →
  10. Aducanumab produced a clinically meaningful benefit in association with amyloid lowering
    2021 155 citations Jeffrey L. Cummings, Paul Aisen et al. profile →
  11. Aducanumab: Appropriate Use Recommendations Update
    2022 126 citations Jeffrey L. Cummings, Gil D. Rabinovici et al. The Journal of Prevention of Alzheimer s Disease profile →
  12. Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease
    2025 29 citations Jennifer A. Zimmer, Paul Ardayfio et al. JAMA Neurology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Stephen Salloway 5.9k 5.1k 2.8k 2.6k 2.2k 180 13.9k
Frederick A. Schmitt 7.7k 1.3× 6.8k 1.3× 3.1k 1.1× 2.1k 0.8× 3.1k 1.4× 273 18.0k
John C.S. Breitner 8.1k 1.4× 9.4k 1.9× 3.3k 1.2× 1.7k 0.6× 1.9k 0.9× 279 21.2k
Elaine R. Peskind 7.9k 1.3× 5.6k 1.1× 2.8k 1.0× 4.1k 1.6× 2.7k 1.2× 294 23.0k
Rema Raman 4.5k 0.8× 3.3k 0.7× 1.4k 0.5× 2.3k 0.9× 1.6k 0.7× 232 13.0k
Michael Grundman 7.0k 1.2× 5.9k 1.2× 2.4k 0.9× 1.6k 0.6× 1.7k 0.8× 115 14.8k
Gordon Wilcock 5.6k 1.0× 4.3k 0.8× 2.5k 0.9× 1.2k 0.5× 2.0k 0.9× 226 14.7k
Kathleen A. Welsh‐Bohmer 5.0k 0.8× 5.8k 1.2× 1.6k 0.6× 1.5k 0.6× 2.5k 1.1× 233 14.7k
Sharon X. Xie 4.9k 0.8× 3.9k 0.8× 1.9k 0.7× 5.6k 2.2× 2.1k 0.9× 223 15.1k
Florence Pasquier 6.7k 1.1× 8.8k 1.7× 3.7k 1.4× 3.6k 1.4× 3.4k 1.5× 362 19.1k
José Luís Molinuevo 6.3k 1.1× 6.9k 1.4× 2.8k 1.0× 4.7k 1.8× 4.4k 2.0× 347 18.6k

Countries citing papers authored by Stephen Salloway

Since Specialization
Citations

This map shows the geographic impact of Stephen Salloway's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen Salloway with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen Salloway more than expected).

Fields of papers citing papers by Stephen Salloway

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen Salloway. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen Salloway. The network helps show where Stephen Salloway may publish in the future.

Co-authorship network of co-authors of Stephen Salloway

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen Salloway. A scholar is included among the top collaborators of Stephen Salloway based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen Salloway. Stephen Salloway is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Siemers, Eric, Gopalan Sethuraman, Karen Sundell, et al.. (2025). INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease. The Journal of Prevention of Alzheimer s Disease. 12(1). 100005–100005. 4 indexed citations
2.
Wang, Hong, Emel Serap Monkul Nery, Paul Ardayfio, et al.. (2025). The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6. The Journal of Prevention of Alzheimer s Disease. 12(8). 100266–100266. 2 indexed citations
3.
Angioni, Davide, Lefkos Middleton, Randall J. Bateman, et al.. (2025). Challenges and opportunities for novel combination therapies in Alzheimer's disease: a report from the EU/US CTAD Task Force. The Journal of Prevention of Alzheimer s Disease. 12(6). 100163–100163. 2 indexed citations
4.
Wang, Hong, Emel Serap Monkul Nery, Paul Ardayfio, et al.. (2025). Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction. Alzheimer s & Dementia. 21(4). e70062–e70062. 10 indexed citations
5.
Chen, Tianle, John O’Gorman, Carmen Castrillo‐Viguera, et al.. (2024). Results from the long‐term extension of PRIME: A randomized Phase 1b trial of aducanumab. Alzheimer s & Dementia. 20(5). 3406–3415. 11 indexed citations
6.
Thompson, Louisa I., Alyssa N. De Vito, Zachary J. Kunicki, et al.. (2024). Psychometric and adherence considerations for high-frequency, smartphone-based cognitive screening protocols in older adults. Journal of the International Neuropsychological Society. 30(8). 785–793. 4 indexed citations
7.
Mintun, Mark A., Craig Ritchie, Paul R. Solomon, et al.. (2024). 1978 Donanemab in early symptomatic Alzheimer’s Disease: Efficacy and safety in TRAILBLAZER-ALZ 2, Phase 3 Randomized Clinical Trial. Age and Ageing. 53(Supplement_1). 2 indexed citations
8.
Chin, Nathaniel A., et al.. (2024). Alzheimer’s Disease — Managing Stages of Dementia. New England Journal of Medicine. 390(12). e29–e29. 5 indexed citations
9.
Salloway, Stephen, Nicola Voyle, Christopher Lane, et al.. (2024). Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease. JAMA Neurology. 82(1). 19–19. 15 indexed citations
10.
Mintun, Mark A., Craig Ritchie, Paul R. Solomon, et al.. (2023). Donanemab in Early Symptomatic Alzheimer’s Disease: Efficacy and Safety in TRAILBLAZER‐ALZ 2, a Phase 3 Randomized Clinical Trial. Alzheimer s & Dementia. 19(S24). 6 indexed citations
11.
Griffin, Percy, Liana G. Apostolova, Bradford C. Dickerson, et al.. (2023). Developments in understanding early onset Alzheimer's disease. Alzheimer s & Dementia. 19(S9). S126–S131. 11 indexed citations
12.
Thompson, Louisa I., Zachary J. Kunicki, Sheina Emrani, et al.. (2023). Remote and in‐clinic digital cognitive screening tools outperform the MoCA to distinguish cerebral amyloid status among cognitively healthy older adults. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring. 15(4). e12500–e12500. 16 indexed citations
13.
Mintun, Mark A., Albert Lo, Cynthia Evans, et al.. (2021). Donanemab in Early Alzheimer’s Disease. New England Journal of Medicine. 384(18). 1691–1704. 969 indexed citations breakdown →
14.
Dubois, Bruno, Nicolas Villain, Giovanni B. Frisoni, et al.. (2021). Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. The Lancet Neurology. 20(6). 484–496. 598 indexed citations breakdown →
15.
Salloway, Stephen, Kumar Budur, Ronald B. DeMattos, et al.. (2020). Advancing combination therapy for Alzheimer's disease. Alzheimer s & Dementia Translational Research & Clinical Interventions. 6(1). e12073–e12073. 42 indexed citations
16.
Castillo-Barnés, Diego, Li Su, Javier Ramı́rez, et al.. (2020). Autosomal dominantly inherited alzheimer disease: Analysis of genetic subgroups by machine learning. Information Fusion. 58. 153–167. 15 indexed citations
17.
Asken, Breton M., Kelsey R. Thomas, Athene Lee, et al.. (2019). Discrepancy-Based Evidence for Loss of Thinking Abilities (DELTA): Development and Validation of a Novel Approach to Identifying Cognitive Changes. Journal of the International Neuropsychological Society. 26(5). 464–479. 3 indexed citations
18.
Viglietta, Vissia, John O’Gorman, Leslie Williams, et al.. (2016). Randomized, Double-Blind, Placebo-Controlled Studies to Evaluate Treatment with Aducanumab (BIIB037) in Patients with Early Alzheimer’s Disease: Phase 3 Study Design (S1.003). Neurology. 86(16_supplement). 9 indexed citations
19.
Salloway, Stephen, Patricia A. Boyle, Stephen Correia, et al.. (2002). The Relationship of MRI Subcortical Hyperintensities to Treatment Response in a Trial of Sertraline in Geriatric Depressed Outpatients. American Journal of Geriatric Psychiatry. 10(1). 107–111. 44 indexed citations
20.
Salloway, Stephen, Paul Malloy, & Jeffrey L. Cummings. (1997). The neuropsychiatry of limbic and subcortical disorders. 70 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Frederick A. Schmitt Breakdown of academic impact, for papers by John C.S. Breitner Breakdown of academic impact, for papers by Elaine R. Peskind Breakdown of academic impact, for papers by Rema Raman Breakdown of academic impact, for papers by Michael Grundman Breakdown of academic impact, for papers by Gordon Wilcock Breakdown of academic impact, for papers by Kathleen A. Welsh‐Bohmer Breakdown of academic impact, for papers by Sharon X. Xie Breakdown of academic impact, for papers by Florence Pasquier Breakdown of academic impact, for papers by José Luís Molinuevo
Rankless by CCL
2026